FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056584284> ?p ?o ?g. }

• W2056584284 endingPage "173" @default.
• W2056584284 startingPage "169" @default.
• W2056584284 abstract "Background: We conducted a phase II study to evaluate the efficacy and toxicity of weekly docetaxel combined with epirubicin on D15 as second-line chemotherapy in Taiwanese patients with advanced non small cell lung cancer (NSCLC) who failed or relapsed after the frontline platinum-based chemotherapy. Patients and Methods: Patients with histologically confirmed advanced NSCLC (Stage IIIB–IV) were entered into this Phase II trial. Eastern Cooperative Oncology Group performance status was 0 to 2 and adequate organ function was required. Docetaxel, 30 mg/m2, was given intravenously on days 1, 8, and 15 for 30 minutes and epirubicin, 60 mg/m2, was given intravenously on day 15, then following one week of rest. Treatment was repeated every 4 weeks for a maximal total of 6 cycles. Results: Of the 43 eligible patients, 39 patients were evaluated for response, and all were evaluated for toxicity. The overall response rate was 11.6% [95% confidence interval (CI), 1.6–21.6%]. The median time to disease progression for all patients was 2.8 months (95% CI 1.3–4.3%). The median survival time for all patients was 7.7 months (95% CI 5.5–9.9%). The 1-year survival was 32.6% (95% CI 25.4%–39.7%). The major hematologic toxicities were neutropenia, 8/43 (19%) with grade 3–4 neutropenia, as well as anemia, 6/43 (14%) with grade 3–4 anemia. Nonhematological toxicities were modest. Fatigue was common, 77.8% in all, but only 3 (7%) patients with grade 3–4 toxicities. Diarrhea was also common but not severe, 7/43 (16%) with grade 1–2 episodes, and 1/43 (2%) with grade 3–4 episodes. Nail changes, peripheral edema, lacrimation, and alopecia were mild. Hepatic and renal impairment was also only mild. Conclusion: Combining weekly doses of docetaxel 30 mg/m2 with epirubicin 60 mg/m2 on D15 was not shown to improve both efficacy and tolerability for advanced NSCLC patients who have relapsed disease after frontline platinum-based chemotherapy." @default.
• W2056584284 created "2016-06-24" @default.
• W2056584284 creator A5018216038 @default.
• W2056584284 creator A5027674684 @default.
• W2056584284 creator A5076879172 @default.
• W2056584284 creator A5089337771 @default.
• W2056584284 date "2009-04-01" @default.
• W2056584284 modified "2023-09-26" @default.
• W2056584284 title "Phase II Study of Epirubicin in Combination With Weekly Docetaxel for Patients With Advanced NSCLC Who Have Failed or Relapsed After the Frontline Platinum-Based Chemotherapy" @default.
• W2056584284 cites W1839238860 @default.
• W2056584284 cites W1865725105 @default.
• W2056584284 cites W1883066466 @default.
• W2056584284 cites W1930536528 @default.
• W2056584284 cites W1935885922 @default.
• W2056584284 cites W1970476748 @default.
• W2056584284 cites W1970767487 @default.
• W2056584284 cites W1976347407 @default.
• W2056584284 cites W2031646868 @default.
• W2056584284 cites W2037139573 @default.
• W2056584284 cites W2043696829 @default.
• W2056584284 cites W2053432470 @default.
• W2056584284 cites W2120840070 @default.
• W2056584284 cites W2128420277 @default.
• W2056584284 cites W2130652363 @default.
• W2056584284 cites W2131964390 @default.
• W2056584284 cites W2134667653 @default.
• W2056584284 cites W2138297714 @default.
• W2056584284 cites W2142809967 @default.
• W2056584284 cites W2145081663 @default.
• W2056584284 cites W2153477391 @default.
• W2056584284 cites W2183288147 @default.
• W2056584284 cites W2188493006 @default.
• W2056584284 cites W4231861197 @default.
• W2056584284 cites W4239714259 @default.
• W2056584284 doi "https://doi.org/10.1097/coc.0b013e31817eebdc" @default.
• W2056584284 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19307958" @default.
• W2056584284 hasPublicationYear "2009" @default.
• W2056584284 type Work @default.
• W2056584284 sameAs 2056584284 @default.
• W2056584284 citedByCount "1" @default.
• W2056584284 crossrefType "journal-article" @default.
• W2056584284 hasAuthorship W2056584284A5018216038 @default.
• W2056584284 hasAuthorship W2056584284A5027674684 @default.
• W2056584284 hasAuthorship W2056584284A5076879172 @default.
• W2056584284 hasAuthorship W2056584284A5089337771 @default.
• W2056584284 hasConcept C126322002 @default.
• W2056584284 hasConcept C141071460 @default.
• W2056584284 hasConcept C143998085 @default.
• W2056584284 hasConcept C2776256026 @default.
• W2056584284 hasConcept C2776694085 @default.
• W2056584284 hasConcept C2776755627 @default.
• W2056584284 hasConcept C2776907518 @default.
• W2056584284 hasConcept C2777063308 @default.
• W2056584284 hasConcept C2778248108 @default.
• W2056584284 hasConcept C2778850193 @default.
• W2056584284 hasConcept C2780835546 @default.
• W2056584284 hasConcept C2781190966 @default.
• W2056584284 hasConcept C31760486 @default.
• W2056584284 hasConcept C71924100 @default.
• W2056584284 hasConcept C90924648 @default.
• W2056584284 hasConceptScore W2056584284C126322002 @default.
• W2056584284 hasConceptScore W2056584284C141071460 @default.
• W2056584284 hasConceptScore W2056584284C143998085 @default.
• W2056584284 hasConceptScore W2056584284C2776256026 @default.
• W2056584284 hasConceptScore W2056584284C2776694085 @default.
• W2056584284 hasConceptScore W2056584284C2776755627 @default.
• W2056584284 hasConceptScore W2056584284C2776907518 @default.
• W2056584284 hasConceptScore W2056584284C2777063308 @default.
• W2056584284 hasConceptScore W2056584284C2778248108 @default.
• W2056584284 hasConceptScore W2056584284C2778850193 @default.
• W2056584284 hasConceptScore W2056584284C2780835546 @default.
• W2056584284 hasConceptScore W2056584284C2781190966 @default.
• W2056584284 hasConceptScore W2056584284C31760486 @default.
• W2056584284 hasConceptScore W2056584284C71924100 @default.
• W2056584284 hasConceptScore W2056584284C90924648 @default.
• W2056584284 hasIssue "2" @default.
• W2056584284 hasLocation W20565842841 @default.
• W2056584284 hasLocation W20565842842 @default.
• W2056584284 hasOpenAccess W2056584284 @default.
• W2056584284 hasPrimaryLocation W20565842841 @default.
• W2056584284 hasRelatedWork W1903273130 @default.
• W2056584284 hasRelatedWork W1990777236 @default.
• W2056584284 hasRelatedWork W1998091677 @default.
• W2056584284 hasRelatedWork W2017239577 @default.
• W2056584284 hasRelatedWork W2056584284 @default.
• W2056584284 hasRelatedWork W2058098342 @default.
• W2056584284 hasRelatedWork W2083686235 @default.
• W2056584284 hasRelatedWork W2160583837 @default.
• W2056584284 hasRelatedWork W2397786201 @default.
• W2056584284 hasRelatedWork W2418847095 @default.
• W2056584284 hasVolume "32" @default.
• W2056584284 isParatext "false" @default.
• W2056584284 isRetracted "false" @default.
• W2056584284 magId "2056584284" @default.
• W2056584284 workType "article" @default.